BioWorld

June 23, 2010

Regulus Inks $750M Pre-Target miRNA Deal with Sanofi-Aventis

Regulus Therapeutics Inc. landed its biggest partnership to date: a $750 million deal with Sanofi-Aventis Group SA aimed at discovering microRNA-based drugs against four fibrosis targets. (BioWorld Today) Read More

Diamyd Climbs on $625M Type I Diabetes Deal with Ortho-McNeil

Metabolex, J&J Unit Sign $330M Deal for Type II Diabetes Drugs

Cadence 'Incline'd Toward Pain Market in Late-Stage Option Deal

Corrections & Clarifications

Other News To Note

Stock Movers

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...